SCHEMBL266172

SCHEMBL266172

CCc1ccc(C(=O)O)o1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 4/20 0.67
NPC1 O15118 5/20 0.62
RAB9A P51151 5/20 0.62
KMT2A Q03164 1/20 0.62
POLB P06746 6/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
L3MBTL1 Q9Y468 2/20 0.57
MAPK1 P28482 1/20 0.57
ALDH1A1 P00352 1/20 0.51
ESR1 P03372 1/20 0.51
NR4A1 P22736 1/20 0.51
APEX1 P27695 1/20 0.51
RECQL P46063 1/20 0.51
DUSP3 P51452 1/20 0.51
PTPN5 P54829 1/20 0.51
PTPN11 Q06124 1/20 0.51
ESR2 Q92731 1/20 0.51
CTDSP1 Q9GZU7 1/20 0.51
HTT P42858 2/20 0.50
MAPT P10636 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
2-Ethylfuran SCHEMBL8705055 0.86 TDP1 (0.51) TDP1NPC1RAB9AKMT2APOLB
SCHEMBL8078684 0.84 HTT (0.52) TDP1NPC1RAB9AKMT2APOLB
SCHEMBL13841169 0.83 TDP1 (0.62) TDP1NPC1RAB9AKMT2APOLB
SCHEMBL13078112 0.83 NPC1 (0.47) TDP1NPC1RAB9AKMT2APOLB
SCHEMBL13039993 0.83 NPC1 (0.47) TDP1NPC1RAB9AKMT2APOLB
SCHEMBL27573265 0.83 TDP1 (0.67) TDP1NPC1RAB9AKMT2APOLB
SCHEMBL901472 0.82 TDP1 (0.72) TDP1NPC1RAB9AKMT2APOLB
SCHEMBL4257916 0.81 NPC1 (0.46) TDP1NPC1RAB9AKMT2APOLB
SCHEMBL3297500 0.81 NPC1 (0.46) TDP1NPC1RAB9AKMT2APOLB
SCHEMBL13379467 0.80 TDP1 (0.58) TDP1NPC1RAB9AKMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111655372-B Catalysts containing furans and their use in hydrotreating and/or hydrocracking processes IFP 新能源公司 2023-07-25 CN claimed
US-11027262-B2 Catalyst containing a furan compound and use thereof in a hydroprocessing and/or hydrocracking method IFP Energies Nouvelles (FR) 2021-06-08 US claimed
US-20200391191-A1 CATALYST CONTAINING A FURAN COMPOUND AND USE THEREOF IN A HYDROPROCESSING AND/OR HYDROCRACKING METHOD IFP Energies Nouvelles (FR) 2020-12-17 US claimed
EP-3713669-A1 CATALYST CONTAINING A FURAN COMPOUND AND USE THEREOF IN A HYDROPROCESSING AND/OR HYDROCRACKING METHOD IFP Energies nouvelles (FR) 2020-09-30 EP claimed
CN-111655372-A Catalysts containing furans and use thereof in hydrotreating and/or hydrocracking processes IFP 新能源公司 2020-09-11 CN claimed
EP-0214158-A1 ANTHELMINTIC PYRIDINYL ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS THE UPJOHN COMPANY (US) 1987-03-18 EP claimed
WO-1986004582-A1 ANTHELMINTIC PYRIDINYL ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS THE UPJOHN COMPANY (US) 1986-08-14 WO claimed
US-12408914-B2 Systems and methods for customizing mechanical strength in stimuli-responsive bioabsorbable materials CILAG GMBH INTERNATIONAL (CH) 2025-09-09 US disclosed
EP-4543502-A1 SYSTEMS AND METHODS FOR CUSTOMIZING MECHANICAL STRENGTH IN STIMULI-RESPONSIVE BIOABSORBABLE MATERIALS Cilag GmbH International (CH) 2025-04-30 EP disclosed
US-20250066369-A1 BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES NodThera Limited (GB) 2025-02-27 US disclosed
WO-2024261659-A1 SYSTEMS AND METHODS FOR CUSTOMIZING MECHANICAL STRENGTH IN STIMULI-RESPONSIVE BIOABSORBABLE MATERIALS CILAG GMBH INTERNATIONAL (CH) 2024-12-26 WO disclosed
US-20240423620-A1 COMPRESSIBLE SURGICAL ADJUNCTS, CARTRIDGES, AND CARTRIDGE ASSEMBLIES AND METHODS OF MAKING SURGICAL ADJUNCTS CILAG GMBH INTERNATIONAL (CH) 2024-12-26 US disclosed
US-20240423617-A1 SYSTEMS AND METHODS FOR CUSTOMIZING MECHANICAL STRENGTH IN STIMULI-RESPONSIVE BIOABSORBABLE MATERIALS CILAG GMBH INTERNATIONAL (CH) 2024-12-26 US disclosed
WO-1998042347-A1 PHARMACEUTICAL COMPOSITION CONTAINING A PHOSPHORYLAMIDE AND AN AYNTIBIOTIC TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-10-01 WO disclosed
EP-0852498-A1 PHOSPHORYLAMIDES, THEIR PREPARATION AND USE Takeda Chemical Industries, Ltd. (JP) 1998-07-15 EP disclosed
WO-1997011705-A1 PHOSPHORYLAMIDES, THEIR PREPARATION AND USE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1997-04-03 WO disclosed
US-5023334-A Anthelmintic pyridinyl acylhydrazones THE UPJOHN COMPANY (US) 1991-06-11 US disclosed
US-5011932-A Anthelmintic pyridinyl acylhydrazones derivatives UPJOHN COMPANY (US) 1991-04-30 US disclosed
EP-0214158-A1 ANTHELMINTIC PYRIDINYL ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS THE UPJOHN COMPANY (US) 1987-03-18 EP disclosed
WO-1986004582-A1 ANTHELMINTIC PYRIDINYL ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS THE UPJOHN COMPANY (US) 1986-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066369-A1 BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES IL1B, NLRP3, IL1A TDP1 1374/4885NPC1 1533/4885RAB9A 2808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.